NasdaqCM:LQDAPharmaceuticals
Is Liquidia’s Insider Selling Amid YUTREPIA Momentum Altering The Investment Case For LQDA?
On March 13, 2026, Liquidia’s Chief Medical Officer Rajeev Saggar sold 35,365 shares of common stock for about US$1.28 million, trimming roughly one sixth of his direct holdings.
This sizeable insider sale comes while Liquidia’s core business appears to be progressing, highlighted by YUTREPIA’s reach to more than 2,900 patients and two straight profitable quarters.
We’ll now examine how this sizeable insider sale amid ongoing YUTREPIA momentum may influence Liquidia’s broader investment...